Callhoff J, Weiss A, Zink A, Listing J. Impact of biologic therapy on functional status in patients with rheumatoid arthritis—a meta-analysis. Rheumatology (Oxford). 2013;52(12):2127–35.

Article  CAS  PubMed  Google Scholar 

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–39.

Article  Google Scholar 

Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.

Article  CAS  PubMed  Google Scholar 

Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (Lond, Engl). 2015;386(9990):258–65.

Article  Google Scholar 

Chen C-I, Wang L, Wei W, Yuce H, Phillips K. Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs. Rheumatol Adv Pract. 2018. https://doi.org/10.1093/rap/rky005.

Article  PubMed  PubMed Central  Google Scholar 

Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.

Article  PubMed  Google Scholar 

Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–31.

Article  CAS  PubMed  Google Scholar 

Bechman K, Clarke BD, Rutherford AI, Yates M, Nikiphorou E, Molokhia M, et al. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Rheumatology. 2019;58(10):1767–76.

Article  PubMed  Google Scholar 

Hresko A, Lin TC, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. Arthritis Care Res. 2018;70(10):1431–8.

Article  Google Scholar 

Yazdany J, Tonner C, Schmajuk G. Use and spending for biologic disease-modifying antirheumatic drugs for rheumatoid arthritis among US medicare beneficiaries. Arthritis Care Res. 2015;67(9):1210–8.

Article  Google Scholar 

Kobak S, Bes C. An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(1):3–11.

Article  PubMed  Google Scholar 

Caplan Z, Rabe M. The Older Population: 2020, United States Census Bureau. https://www.census.gov/. Accessed 21 March 2023.

Zhang J, Shan Y, Reed G, Kremer J, Greenberg JD, Baumgartner S, et al. Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. Arthritis Care Res. 2011;63(12):1672–9.

Article  Google Scholar 

Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis. 2008;66(2):77–85.

PubMed  Google Scholar 

Navarro-Millán I, Sattui SE, Curtis JR. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther. 2013;35(11):1850-61.e1.

Article  PubMed  PubMed Central  Google Scholar 

Schett G, Emery P, Tanaka Y, Burmester G, Pisetsky DS, Naredo E, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–37.

Article  CAS  PubMed  Google Scholar 

Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015;42(11):2012–22.

Article  CAS  PubMed  Google Scholar 

Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.

Article  CAS  PubMed  Google Scholar 

Turner JP, Kantilal K, Kantilal K, Holmes HM, Koczwara B. Optimising medications for patients with cancer and multimorbidity: the case for deprescribing. Clin Oncol. 2020;32(9):609–17.

Article  CAS  Google Scholar 

Ouellet GM, Ouellet JA, Tinetti ME. Principle of rational prescribing and deprescribing in older adults with multiple chronic conditions. Ther Adv Drug Saf. 2018;9(11):639–52.

Article  PubMed  PubMed Central  Google Scholar 

Lee J, Singh N, Gray SL, Makris UE. Optimizing medication use in older adults with rheumatic musculoskeletal diseases: deprescribing as an approach when less may be more. ACR Open Rheumatol. 2022;4(12):1031–41.

Article  PubMed  PubMed Central  Google Scholar 

Zhang J, Xie F, Delzell E, Chen L, Kilgore ML, Yun H, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res. 2013;65(11):1743–51.

Article  CAS  Google Scholar 

Solomon DH, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ. Treatment of rheumatoid arthritis in the medicare current beneficiary survey. Arthritis Res Ther. 2013;15(2):R43.

Article  PubMed  PubMed Central  Google Scholar 

Palmowski A, Buttgereit T, Palmowski Y, Nielsen SM, Boers M, Christensen R, et al. Applicability of trials in rheumatoid arthritis and osteoarthritis: a systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. Semin Arthritis Rheum. 2019;48(6):983–9.

Article  PubMed  Google Scholar 

Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol (Hoboken, NJ). 2016;68(1):56–66.

Article  CAS  Google Scholar 

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.

Article  CAS  PubMed  Google Scholar 

Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109(13):1594–602.

Article  CAS  PubMed  Google Scholar 

Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007;57(6):928–34.

Article  PubMed  Google Scholar 

Curtis JR, Xie F, Chen L, Greenberg JD, Zhang J. Evaluation of a methodologic approach to define an inception cohort of rheumatoid arthritis patients using administrative data. Arthritis Care Res. 2018;70(10):1541–5.

Article  Google Scholar 

US Food and Drug Administration: Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed 21 Mar 2023.

Niznik JD, Aspinall SL, Hanson LC, Gilliam MA, Li X, Kelley CJ, et al. Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia. Osteoporosis Int. 2022;33(2):379–90.

Article  CAS  Google Scholar 

Terman SW, Niznik JD, Slinger G, Otte WM, Braun KPJ, Aubert CE, et al. Incidence of and predictors for antiseizure medication gaps in Medicare beneficiaries with epilepsy: a retrospective cohort study. BMC Neurol. 2022;22(1):328.

Article  PubMed  PubMed Central  Google Scholar 

Aslam F, Khan NA. Tools for the assessment of comorbidity burden in rheumatoid arthritis. Front Med. 2018;5:39.

Article  Google Scholar 

Grijalva CG, Chung CP, Stein CM, Gideon PS, Dyer SM, Mitchel EF Jr, et al. Computerized definitions showed high positive predictive values for identifying hospitalizations for congestive heart failure and selected infections in Medicaid enrollees with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2008;17(9):890–5.

Article  PubMed  PubMed Central